cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • dexrazoxane

19d

CY-MET-RIC: Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation (clinicaltrials.gov)

P2, N=82, Not yet recruiting, Nantes University Hospital | N=60 --> 82

19 days ago

Enrollment change • Post-transplantation

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan

19d

CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Guenther Koehne | Trial completion date: Mar 2031 --> Jun 2031 | Trial primary completion date: Mar 2031 --> Jun 2031

19 days ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule)

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

25d

Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases (clinicaltrials.gov)

P2, N=54, Recruiting, Fred Hutchinson Cancer Center | Not yet recruiting --> Recruiting

25 days ago

Enrollment open

KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)

MLL rearrangement • MLL rearrangement

cyclophosphamide • fludarabine IV • thiotepa

NCI-2018-01752: Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)

P2, N=68, Recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025

1 month ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

cyclophosphamide • methotrexate • fludarabine IV • thiotepa • busulfan • methotrexate IV

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=31, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. (PubMed, Oncotarget)

Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the five-drug combination, suggesting a clinical relevance. The results provide a rationale for clinical trials using these two- and five-drug combinations as part of a conditioning regimen for AML patients undergoing HSCT.

1 month ago

Journal

FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • ANXA5 (Annexin A5) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)

Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan

2ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=31, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting

2 months ago

Enrollment open

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

2ms

Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors (clinicaltrials.gov)

P2, N=9, Terminated, Memorial Sloan Kettering Cancer Center | Trial completion date: Jul 2024 --> Mar 2024 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2024 --> Mar 2024; Low accrual

2 months ago

Trial completion date • Trial termination • Trial primary completion date

TP53 (Tumor protein P53) • ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • NUP214 (Nucleoporin 214) • CDKN1A (Cyclin-dependent kinase inhibitor 1A) • DEK (DEK Proto-Oncogene)

TP53 mutation • RUNX1 mutation • KMT2A rearrangement • IKZF1 mutation • MLL mutation • Chr t(9;11)

Rituxan (rituximab) • cyclophosphamide • clofarabine • melphalan • fludarabine IV • thiotepa • busulfan

2ms

Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (clinicaltrials.gov)

P=N/A, N=44, Completed, Masonic Cancer Center, University of Minnesota | Recruiting --> Completed | N=20 --> 44

2 months ago

Trial completion • Enrollment change

MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • CD34 (CD34 molecule)

LDH elevation • MYCN amplification • MYCN expression

carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • thiotepa • busulfan

2ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2027 --> Apr 2025 | Trial primary completion date: Feb 2027 --> Apr 2025

2 months ago

Trial completion date • Trial primary completion date

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

2ms

US Study of ECT-001-CB in Pediatric and Young Adult Patients With High-Risk Myeloid Malignancies (clinicaltrials.gov)

P1/2, N=12, Recruiting, ExCellThera inc. | Trial completion date: Dec 2025 --> Jun 2026 | Trial primary completion date: Dec 2023 --> Jun 2026

2 months ago

Trial completion date • Trial primary completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule)

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan • ECT-001-CB

2ms

Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft (clinicaltrials.gov)

P1, N=40, Recruiting, Stanford University | Trial completion date: Jun 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Dec 2025

2 months ago

Trial completion date • Trial primary completion date • Metastases

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)

Jakafi (ruxolitinib) • cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim) • plerixafor

2ms

HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors (clinicaltrials.gov)

P4, N=250, Active, not recruiting, Nationwide Children's Hospital | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

cisplatin • carboplatin • cyclophosphamide • etoposide IV • vincristine • thiotepa

2ms

P2, N=60, Not yet recruiting, Nantes University Hospital

2 months ago

New P2 trial • Post-transplantation

cyclophosphamide • clofarabine • fludarabine IV • thiotepa • busulfan

2ms

Itacitinib for the Prevention of Graft Versus Host Disease (clinicaltrials.gov)

P1, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

2 months ago

Enrollment closed

cyclophosphamide • fludarabine IV • thiotepa • busulfan • itacitinib (INCB039110)

3ms

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (clinicaltrials.gov)

P2, N=103, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • DNMT3A (DNA methyltransferase 1) • NF1 (Neurofibromin 1) • RUNX1 (RUNX Family Transcription Factor 1) • ASXL1 (ASXL Transcriptional Regulator 1) • PTPN1 (Protein Tyrosine Phosphatase Non-Receptor Type 1)

TP53 mutation • KRAS mutation • NRAS mutation • RAS mutation

Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan

3ms

NCI-2017-02205: Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes (clinicaltrials.gov)

P2, N=20, Recruiting, Fred Hutchinson Cancer Center | Suspended --> Recruiting | N=15 --> 20

3 months ago

Enrollment open • Enrollment change

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • HLA-B (Major Histocompatibility Complex, Class I, B)

cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)

3ms

HAP2HCT: TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (clinicaltrials.gov)

P2, N=140, Active, not recruiting, St. Jude Children's Research Hospital | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

FLT3 (Fms-related tyrosine kinase 3) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • ETV6 (ETS Variant Transcription Factor 6) • WT1 (WT1 Transcription Factor) • CREBBP (CREB binding protein) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • NSD1 (Nuclear Receptor Binding SET Domain Protein 1) • HOXA9 (Homeobox A9) • NUP214 (Nucleoporin 214) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GLIS2 (GLIS Family Zinc Finger 2) • KAT6A (Lysine Acetyltransferase 6A) • KDM5A (Lysine Demethylase 5A) • DEK (DEK Proto-Oncogene) • AFDN (Afadin, Adherens Junction Formation Factor) • MLLT10 (MLLT10 Histone Lysine Methyltransferase DOT1L Cofactor)

FLT3-ITD mutation • WT1 mutation • MLL fusion • NUP98-NSD1 fusion

cyclophosphamide • Blincyto (blinatumomab) • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)

3ms

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant (clinicaltrials.gov)

P2, N=59, Recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Apr 2024 --> Apr 2025 | Trial primary completion date: Apr 2024 --> Apr 2025

3 months ago

Trial completion date • Trial primary completion date

TP53 (Tumor protein P53) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CD34 (CD34 molecule) • CD4 (CD4 Molecule)

TP53 mutation

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

4ms

Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)

P1, N=33, Recruiting, City of Hope Medical Center

4 months ago

New P1 trial

melphalan • fludarabine IV • thiotepa • Orca-T

4ms

Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (clinicaltrials.gov)

P2, N=135, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2024

4 months ago

Trial completion date

HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)

cyclophosphamide • fludarabine IV • thiotepa

4ms

Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)

P2, N=82, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024

4 months ago

Trial completion date • Trial primary completion date

CD34 (CD34 molecule) • CD4 (CD4 Molecule)

Chr t(15;17)

cyclophosphamide • Firmagon (degarelix) • thiotepa • leuprolide acetate for depot suspension • Kepivance (palifermin)

4ms

A Phase II Pediatric Study of a Graft-VS.-Host Disease (GVHD) Prophylaxis Regimen With no Calcineurin Inhibitors After Day +60 Post First Allogeneic Hematopoietic Cell Transplant for Hematological Malignancies (clinicaltrials.gov)

P2, N=32, Recruiting, St. Jude Children's Research Hospital

4 months ago

Trial completion date • Trial primary completion date

Jakafi (ruxolitinib) • cyclophosphamide • fludarabine IV • thiotepa • busulfan

4ms

Evidence-based management of primary and secondary CNS lymphoma. (PubMed, Semin Hematol)

Intensive high-dose methotrexate-containing induction followed by consolidation with autologous stem cell transplantation with thiotepa-based conditioning is recommended for patients who are fit...Data regarding the efficacy of chimeric antigen receptor T-cells therapy is emerging, and concerns regarding greater toxicity have not been realized. Future areas of prospective studies include the identification of those at high risk of developing CNS lymphoma, management in elderly or frail patients as well as incorporating novel agents into regimens, particularly for those with chemoresistant disease.

4 months ago

Journal

CRBN (Cereblon)

methotrexate • thiotepa

4ms

Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS (clinicaltrials.gov)

P2, N=22, Completed, Randy Windreich | Active, not recruiting --> Completed | Trial completion date: Nov 2023 --> Apr 2023 | Trial primary completion date: Nov 2023 --> Apr 2023

4 months ago

Trial completion • Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3) • CD34 (CD34 molecule)

FLT3 positive

Campath (alemtuzumab) • melphalan • fludarabine IV • hydroxyurea • thiotepa • busulfan

5ms

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (clinicaltrials.gov)

P3, N=478, Not yet recruiting, National Cancer Institute (NCI)

5 months ago

New P3 trial

ALK (Anaplastic lymphoma kinase) • TERT (Telomerase Reverse Transcriptase) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor)

cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • irinotecan • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • dexrazoxane

5ms

Thiotepa Plus Fludarabine+ Melphalan as the Preparative Regime for Alternative Donor Transplantation (clinicaltrials.gov)

P2, N=40, Active, not recruiting, Case Comprehensive Cancer Center | Trial completion date: Dec 2025 --> Jun 2025 | Trial primary completion date: Dec 2023 --> Jun 2024

5 months ago

Trial completion date • Trial primary completion date

FLT3 (Fms-related tyrosine kinase 3)

FLT3 mutation

fludarabine IV • thiotepa • captisol-enabled melphalan

5ms

CD34+ Transplants for Leukemia and Lymphoma (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Baptist Health South Florida | Trial completion date: Dec 2030 --> Mar 2031

5 months ago

Trial completion date

CD34 (CD34 molecule)

cyclophosphamide • melphalan • fludarabine IV • thiotepa • busulfan

5ms

ABCD-NK: Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML (clinicaltrials.gov)

P1/2, N=48, Not yet recruiting, Washington University School of Medicine

5 months ago

New P1/2 trial

melphalan • fludarabine IV • thiotepa • busulfan • plerixafor

5ms

Excellent Outcomes Using a Non-Myeloablative Conditioning with Thiotepa and Post -Transplant Cyclophosphamide in Adults Undergoing a Matched Related Donor Bone Marrow Transplant for Severe Sickle Cell Disease (TCT-ASTCT-CIBMTR 2024)

The conditioning regimen included: rabbit anti-thyroglobulin (ATG), Thiotepa, Fludarabine, Cyclophosphamide, and total body irradiation (TBI). GVHD prophylaxis included PTCy, mycophenolate mofetil (MMF), and Sirolimus, Figure 3...The filgrastim mobilized stem cell source was PB in 54.5% and BM in 45.5%... This result shows excellent outcomes using Thiotepa based conditioning with PTCy for MSD or MMRD for adults with SCD. The toxicity was low, with no mortality or chronic GVHD, and well tolerated with a second transplant. The optimal donor engraftment (>90% donor chimerism) will help mitigate against the risk of secondary myeloid neoplasm.

5 months ago

Clinical • Post-transplantation

CD34 (CD34 molecule)

cyclophosphamide • sirolimus • fludarabine IV • thiotepa • Neupogen (filgrastim)

5ms

Conditioning was myeloablative busulfan with pharmacokinetic monitoring and fludarabine +/- cyclophosphamide/thiotepa or a reduced intensity melphalan-based regimen with fludarabine. All patients received serotherapy with ATG or alemtuzumab. Post-PSCT immune suppression was none or mycophenolate mofetil (MMF) and/or a calcineurin inhibitor (CNI)... 41 patients with a variety of IEIs were included (Figure 1). At a median follow-up of 2.5 years, OS was 85% (95% CI 75-97%) and EFS 80% (95% CI 69-94%), but was variable by underlying disease (Figure 2). Three patients experienced graft failure (7.3%), two requiring a second transplant and one receiving donor lymphocyte infusion only.

5 months ago

Clinical

CD4 (CD4 Molecule)

cyclophosphamide • Campath (alemtuzumab) • melphalan • fludarabine IV • thiotepa • busulfan

5ms

Car-T Pre-HSCT and Prophylactic Haplo-DLI Post-HSCT and Tcrαβ-Depleted Haploidentical Stem Cell Transplantation: Decreased the Relapse Rate and Improve the Transplant Outcome in Pediatric R/R-ALL (TCT-ASTCT-CIBMTR 2024)

The conditioning consisted of Cyclophosphamide (1 × 50 mg/kg, days −10, -3 to -2), Fudarabine (1 × 40 mg/m2, days -7 to -4), Thiotepa (2 × 5 mg/kg, day -4), Bu ( total 90 mg/m2, days -7 to -5) , Anti-thymocyte globulin (ATG-F) (1 × 15 mg/kg,days -9 to -8 ). With a median follow-up of 431 (range, 16-1062) days for surviving patients. The median time to neutrophil and platelet engraftment was 17 (range, 10–22) and 9 (range, 6–12) days, respectively. Three children experienced primary graft failure.

5 months ago

Clinical

CD22 (CD22 Molecule) • CD7 (CD7 Molecule)

cyclophosphamide • thiotepa

5ms

Clinical Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation Using Busulfan/Cyclophosphamide and Melphalan or Thiotepa As Conditioning Regimen in 37 Patients with Acute Megakaryoblastic Leukemia (ASH 2023)

The conditioning regimens administered were modified Bu/Cy (fludarabine 30 mg/m 2/d×5d; cytarabine 2g/m 2/d×5d; Bu 3...8g/m 2/d×2d; etoposide 100mg/m 2/d×2d; antithymocyte globulin 1...Cyclosporine A (CSA)+ mycophenolate mofetil (MMF)+ short methotrexate (sMTX) were used as graft-versus-host disease (GVHD) prophylaxis...Therefore, it is strongly recommended that allo-HSCT is performed in CR status. However, to corroborate these findings, it is essential to conduct long-term, large-scale clinical research across multiple centers.

5 months ago

Clinical • Clinical data

NRAS (Neuroblastoma RAS viral oncogene homolog) • JAK2 (Janus kinase 2) • ASXL1 (ASXL Transcriptional Regulator 1) • TET2 (Tet Methylcytosine Dioxygenase 2) • PTPN11 (Protein Tyrosine Phosphatase Non-Receptor Type 11) • WT1 (WT1 Transcription Factor) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • CD34 (CD34 molecule) • CBFA2T3 (CBFA2/RUNX1 Partner Transcriptional Co-Repressor 3) • GATA1 (GATA Binding Protein 1) • GLIS2 (GLIS Family Zinc Finger 2) • KDM5A (Lysine Demethylase 5A)

WT1 mutation

cytarabine • cyclophosphamide • etoposide IV • methotrexate • melphalan • fludarabine IV • thiotepa • busulfan

5ms

Methotrexate in Combination with Orelabrutinib, Thiotepa, and Rituximab (R-MTO) Followed By Autologous Stem-Cell Transplant for Primary Central Nervous System Lymphoma Treatment (ASH 2023)

The HCT regimen involved busulfan 3. 2 mg/kg on days -5, -4, thiotepa 250 mg/m 2 on days -7 and -6, cytarabine 2g/m 2 q12h on days -3 and -2, followed by reinfusion of stem cells on day 0... The R-MTO induction treatment has demonstrated notable efficacy in achieving higher response rates among patients with PCNSL, and the associated adverse events are manageable.

5 months ago

Combination therapy

TP53 (Tumor protein P53)

TP53 mutation

Rituxan (rituximab) • cytarabine • methotrexate • Yinuokai (orelabrutinib) • thiotepa • busulfan

5ms

Phase II, Single-Center, Prospective Study of Intrathecal Thiotepa for the Prophylaxis of Secondary Central Nervous System Involvement in Highly Aggressive B-Cell Lymphoma (ASH 2023)

Evidence supporting the use of intravenous methotrexate (MTX) or arabinoside (AraC) in high-risk patients is growing, however, the use of other agents remains to be defined...All patients are need to receive IT thiotepa 10 mg and dexamethasone 5 mg on day 1 of each cycle of chemotherapy for at least 4 cycles...6%) patients received rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (RCHOP), 5 (18...1%) patients received BTK inhibitor, lenalidomide with rituximab (ZR2) followed by RCHOP, and 4 (14...ConclusionProphylactic intrathecal thiotepa is an effective and side-effects manageable measure for preventing secondary central nervous system involvement in high-risk DLBCL. Longer follow-up and larger-scale prospective trial is needed to testify this measure.

5 months ago

Clinical • P2 data • IO biomarker

TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)

TP53 deletion

Rituxan (rituximab) • lenalidomide • doxorubicin hydrochloride • cyclophosphamide • vincristine • thiotepa

5ms

Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers (clinicaltrials.gov)

P2, N=10, Recruiting, Fred Hutchinson Cancer Center | Trial primary completion date: Nov 2022 --> Dec 2024

5 months ago

Trial primary completion date

MLL rearrangement • MLL rearrangement

cyclophosphamide • fludarabine IV • thiotepa • dilanubicel (DVX101)